Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Dietary Intake of Lipid-Soluble Micronutrients
2.3. Ascertainment of Outcomes
2.4. Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chalasani, N.; Younossi, Z.; La Vine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2017, 67, 328–357. [Google Scholar] [CrossRef]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55, 2005–2023. [Google Scholar] [CrossRef]
- Le, M.H.; Yeo, Y.H.; Cheung, R.; Wong, V.W.-S.; Nguyen, M.H. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J. Intern. Med. 2020, 287, 711–722. [Google Scholar] [CrossRef] [PubMed]
- Ruhl, C.E.; Everhart, J.E. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment. Pharmacol. Ther. 2014, 41, 65–76. [Google Scholar] [CrossRef]
- Day, C.P.; James, O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842–845. [Google Scholar] [CrossRef]
- Tilg, H.; Moschen, A. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836–1846. [Google Scholar] [CrossRef]
- Schuppan, D.; Schattenberg, J.M. Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J. Gastroenterol. Hepatol. 2013, 28 (Suppl. S1), 68–76. [Google Scholar]
- Jenab, M.; Slimani, N.; Bictash, M.; Ferrari, P.; Bingham, S.A. Biomarkers in nutritional epidemiology: Applications, needs and new horizons. Hum. Genet. 2009, 125, 507–525. [Google Scholar] [CrossRef] [PubMed]
- Rao, A.V.; Rao, L.G. Carotenoids and human health. Pharmacol. Res. 2007, 55, 207–216. [Google Scholar] [CrossRef]
- Cicero, A.F.G.; Colletti, A.; Bellentani, S. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients 2018, 10, 1153. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Keane, J.T.; Elangovan, H.; Stokes, R.A.; Gunton, J.E. Vitamin D and the Liver-Correlation or Cause? Nutrients 2018, 10, 496. [Google Scholar] [CrossRef] [Green Version]
- Nagashimada, M.; Ota, T. Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life 2018, 71, 516–522. [Google Scholar] [CrossRef] [PubMed]
- Christensen, K.; Lawler, T.; Mares, J. Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003–2014. Nutrients 2019, 11, 1101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perumpail, B.J.; Cholankeril, R.; Yoo, E.R.; Kim, D.; Ahmed, A. An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease. Diseases 2017, 5, 23. [Google Scholar] [CrossRef] [PubMed]
- Della Pepa, G.; Vetrani, C.; Lombardi, G.; Bozzetto, L.; Annuzzi, G.; Rivellese, A.A. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients 2017, 9, 1065. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Erhardt, A.; Stahl, W.; Sies, H.; Lirussi, F.; Donner, A.; Haussinger, D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur. J. Med. Res. 2011, 16, 76–78. [Google Scholar] [CrossRef]
- Bahcecioglu, I.H.; Yalniz, M.; Ilhan, N.; Ataseven, H.; Ozercan, I.H. Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis: Relationship with histopathologic severity. Int. J. Clin. Pract. 2005, 59, 318–323. [Google Scholar] [CrossRef]
- Rinella, M.E. Nonalcoholic fatty liver disease: A systematic review. JAMA 2015, 313, 2263–2273. [Google Scholar] [CrossRef]
- Amanullah, I.; Khan, Y.H.; Anwar, I.; Gulzar, A.; Mallhi, T.H.; Raja, A.A. Effect of vitamin E in non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomised controlled trials. Postgrad. Med. J. 2019, 95, 601–611. [Google Scholar] [CrossRef]
- Sato, K.; Gosho, M.; Yamamoto, T.; Kobayashi, Y.; Ishii, N.; Ohashi, T.; Nakade, Y.; Ito, K.; Fukuzawa, Y.; Yoneda, M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Nutrition 2015, 31, 923–930. [Google Scholar] [CrossRef]
- Arteh, J.; Narra, S.; Nair, S. Prevalence of Vitamin D Deficiency in Chronic Liver Disease. Dig. Dis. Sci. 2009, 55, 2624–2628. [Google Scholar] [CrossRef] [PubMed]
- Barchetta, I.; Angelico, F.; Del Ben, M.; Baroni, M.G.; Pozzilli, P.; Morini, S.; Cavallo, M.G. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011, 9, 85. [Google Scholar] [CrossRef]
- Targher, G.; Bertolini, L.; Scala, L.; Cigolini, M.; Zenari, L.; Falezza, G.; Arcaro, G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 517–524. [Google Scholar] [CrossRef]
- Chung, G.E.; Kim, D.; Kwak, M.S.; Yang, J.I.; Yim, J.Y.; Lim, S.H.; Itani, M. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2016, 22, 146–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.; Liu, Y.; Wan, B.; Zhang, H.; Wu, S.; Zhu, Z.; Lin, Y.; Wang, M.; Zhang, N.; Lin, S.; et al. Association between Vitamin D Status and Non-Alcoholic Fatty Liver Disease: A Population-Based Study. J. Nutr. Sci. Vitaminol. 2019, 65, 303–308. [Google Scholar] [CrossRef] [Green Version]
- Rich, N.E.; Oji, S.; Mufti, A.R.; Browning, J.D.; Parikh, N.D.; Odewole, M.; Mayo, H.; Singal, A.G. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2018, 16, 198–210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tabibian, J.H.; Lazo, M.; Durazo, F.A.; Yeh, H.C.; Tong, M.J.; Clark, J.M. Nonalcoholic fatty liver disease across ethno-racial groups: Do Asian-American adults represent a new at-risk population? J. Gastroenterol. Hepatol. 2011, 26, 501–509. [Google Scholar] [CrossRef] [Green Version]
- Saab, S.; Manne, V.; Nieto, J.; Schwimmer, J.; Chalasani, N.P. Nonalcoholic Fatty Liver Disease in Latinos. Clin. Gastroenterol. Hepatol. 2015, 14, 5–12. [Google Scholar] [CrossRef] [Green Version]
- Paik, J.M.; Henry, L.; De Avila, L.; Younossi, E.; Racila, A.; Younossi, Z.M. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol. Commun. 2019, 3, 1459–1471. [Google Scholar] [CrossRef] [Green Version]
- Peeri, N.C.; Chai, W.; Cooney, R.V.; Tao, M.-H. Association of serum levels of antioxidant micronutrients with mortality in US adults: National Health and Nutrition Examination Survey 1999–2002. Public Health Nutr. 2020, 1–10. [Google Scholar] [CrossRef]
- National Center for Health Statistics. National Health and Nutrition Examination Survey. Available online: http://www.cdc.gov/nchs/nhanes/ (accessed on 2 June 2021).
- Ahluwalia, N.; Dwyer, J.; Terry, A.; Moshfegh, A.; Johnson, C. Update on NHANES Dietary Data: Focus on Collection, Release, Analytical Considerations, and Uses to Inform Public Policy. Adv. Nutr. 2016, 7, 121–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moshfegh, A.J.; Rhodes, D.G.; Baer, D.J.; Murayi, T.; Clemens, J.C.; Rumpler, W.V.; Paul, D.R.; Sebastian, R.; Kuczynski, K.J.; Ingwersen, L.A.; et al. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am. J. Clin. Nutr. 2008, 88, 324–332. [Google Scholar] [CrossRef] [PubMed]
- National Health and Nutrition Examination Survey. Liver Ultrasound Transient Elastography Procedures Manual. 2018. Available online: https://wwwn.cdc.gov/nchs/data/nhanes/2017–2018/manuals/2018_Liver_Ultrasound_Elastography_Procedures_Manual.pdf (accessed on 2 June 2021).
- Myers, R.P.; Pollett, A.; Kirsch, R.; Pomier-Layrargues, G.; Beaton, M.; Levstik, M.; Duarte-Rojo, A.; Wong, D.; Crotty, P.; Elkashab, M. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012, 32, 902–910. [Google Scholar] [CrossRef] [PubMed]
- de Ledinghen, V.; Wong, G.L.; Vergniol, J.; Chan, H.L.; Hiriart, J.B.; Chan, A.W.; Chermak, F.; Choi, P.C.; Foucher, J.; Chan, C.K.; et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016, 31, 848–855. [Google Scholar] [CrossRef] [PubMed]
- Sasso, M.; Audiere, S.; Kemgang, A.; Gaouar, F.; Corpechot, C.; Chazouilleres, O.; Fournier, C.; Golsztejn, O.; Prince, S.; Menu, Y.; et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: A pilot study assessing diagnostic accuracy. Ultrasound Med. Biol. 2016, 42, 92–103. [Google Scholar] [CrossRef]
- Eddowes, P.J.; Sasso, M.; Allison, M.; Tsochatzis, E.; Anstee, Q.M.; Sheridan, D.; Guha, I.N.; Cobbold, J.F.; Deeks, J.J.; Paradis, V.; et al. Accuracy of FibroScan controlled attenuation parameter and Liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019, 156, 1717–1730. [Google Scholar] [CrossRef] [Green Version]
- Division of the National Health and Nutrition Examination Surveys. The National Health and Nutrition Examination Survey (Nhanes) Analytic and Reporting Guidelines; U.S. Government Publishing Office: Washington, DC, USA, 2020; Volume 2020. [Google Scholar]
- Tsou, P.; Wu, C.J. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J. Clin. Med. 2019, 8, 1057. [Google Scholar] [CrossRef] [Green Version]
- Marchisello, S.; Di Pino, A.; Scicali, R.; Urbano, F.; Piro, S.; Purrello, F.; Rabuazzo, A.M. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int. J. Mol. Sci. 2019, 20, 1948. [Google Scholar] [CrossRef] [Green Version]
- Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A.; et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675–1685. [Google Scholar] [CrossRef] [Green Version]
- Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N.; et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011, 305, 1659–1668. [Google Scholar] [CrossRef] [Green Version]
- Ma, C.; Liu, Y.; He, S.; Zeng, J.; Li, P.; Ma, C.; Ping, F.; Zhang, H.; Xu, L.; Li, W.; et al. Negative association between antioxidant vitamin intake and non-alcoholic fatty liver disease in Chinese non-diabetic adults: Mediation models involving superoxide dismutase. Free Radic. Res. 2020, 54, 670–677. [Google Scholar] [CrossRef] [PubMed]
- Lotfi, A.; Saneei, P.; Hekmatdost, A.; Salehisahlabadi, A.; Shiranian, A.; Ghiasvand, R. The relationship between dietary antioxidant intake and physical activity rate with nonalcoholic fatty liver disease (NAFLD): A case control study. Clin. Nutr. ESPEN 2019, 34, 45–49. [Google Scholar] [CrossRef] [PubMed]
- Vos, M.B.; Colvin, R.; Belt, P.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Schwimmer, J.B.; Tonascia, J.; Unalp, A.; Lavine, J.E.; et al. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 90–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ivancovsky-Wajcman, D.; Fliss-Isakov, N.; Salomone, F.; Webb, M.; Shibolet, O.; Kariv, R.; Zelber-Sagi, S. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig. Liver Dis. 2019, 51, 1698–1705. [Google Scholar] [CrossRef] [Green Version]
- Walker, R.W.; Belbin, G.M.; Sorokin, E.P.; Van Vleck, T.; Wojcik, G.L.; Moscati, A.; Gignoux, C.R.; Cho, J.; Abul-Husn, N.S.; Nadkarni, G.; et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J. Hepatol. 2020, 72, 1070–1081. [Google Scholar] [CrossRef] [PubMed]
- Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.; Boerwinkle, E.; Cohen, J.C.; Hobbs, H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40, 1461–1465. [Google Scholar] [CrossRef] [Green Version]
- Edelman, D.; Kalia, H.; Delio, M.; Alani, M.; Krishnamurthy, K.; Abd, M.; Auton, A.; Wang, T.; Wolkoff, A.W.; Morrow, B.E. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean–Hispanic population. Mol. Genet. Genom. Med. 2015, 3, 558–569. [Google Scholar] [CrossRef]
- Goran, M.I.; Walker, R.; Le, K.-A.; Mahurkar, S.; Vikman, S.; Davis, J.N.; Spruijt-Metz, N.; Weigensberg, M.J.; Allayee, H. Effects of PNPLA3 on Liver Fat and Metabolic Profile in Hispanic Children and Adolescents. Diabetes 2010, 59, 3127–3130. [Google Scholar] [CrossRef] [Green Version]
- Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alfoldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv 2019, 531210. [Google Scholar]
- Xu, R.; Tao, A.; Zhang, S.; Deng, Y.; Chen, G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: A HuGE review and meta-analysis. Sci. Rep. 2015, 5, 9284. [Google Scholar] [CrossRef] [PubMed]
- Jablonski, N.G.; Chaplin, G. The roles of vitamin D and cutaneous vitamin D production in human evolution and health. Int. J. Paleopathol. 2018, 23, 54–59. [Google Scholar] [CrossRef]
- Forrest, K.Y.; Stuhldreher, W.L. Prevalence and correlates of vitamin D deficiency in US adults. Nutr. Res. 2011, 31, 48–54. [Google Scholar] [CrossRef] [PubMed]
- Romero-Gomez, M.; Zelber-Sagi, S.; Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017, 67, 829–846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eggersdorfer, M.; Wyss, A. Carotenoids in human nutrition and health. Arch. Biochem. Biophys. 2018, 652, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Krinsky, N.I.; Johnson, E.J. Carotenoid actions and their relation to health and disease. Mol. Asp. Med. 2005, 26, 459–516. [Google Scholar] [CrossRef]
- Seif El-Din, S.H.; El-Lakkany, N.M.; El-Naggar, A.A.; Hammam, O.A.; Abd El-Latif, H.A.; Ain-Shoka, A.A.; Ebeid, F.A. Effects of rosuvastatin and/or beta-carotene on non-alcoholic fatty liver in rats. Res. Pharm. Sci. 2015, 10, 275–287. [Google Scholar] [PubMed]
- Wang, L.; Ding, C.; Zeng, F.; Zhu, H. Low Levels of Serum beta-carotene and beta-carotene/retinol ratio are associated with histological severity in nonalcoholic fatty liver disease patients. Ann. Nutr. Metab. 2019, 74, 156–164. [Google Scholar] [CrossRef]
- Kimura, M.; Mikami, K.; Endo, T.; Matsuzaka, M.; Sawada, N.; Igarashi, G.; Iino, C.; Hasegawa, T.; Sawada, K.; Ando, M.; et al. Association between serum beta-carotene-to-retinol ratio and severity of hepatic steatosis in non-alcoholic fatty liver disease in Japan: A cross-sectional study. Nutrition 2020, 79–80, 110984. [Google Scholar] [CrossRef]
- Xiao, M.-L.; Chen, G.-D.; Zeng, F.-F.; Qiu, R.; Shi, W.-Q.; Lin, J.-S.; Cao, Y.; Li, H.-B.; Ling, W.-H.; Chen, Y.-M. Higher serum carotenoids associated with improvement of non-alcoholic fatty liver disease in adults: A prospective study. Eur. J. Nutr. 2018, 58, 721–730. [Google Scholar] [CrossRef]
- Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029–1035. [Google Scholar] [CrossRef]
- Bjelakovic, G.; Nikolova, D.; Gluud, C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: Do we have evidence for lack of harm? PLoS ONE 2013, 8, e74558. [Google Scholar] [CrossRef]
- Ford, E.S.; Schleicher, R.L.; Mokdad, A.H.; Ajani, U.A.; Liu, S. Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. Am. J. Clin. Nutr. 2006, 84, 375–383. [Google Scholar] [CrossRef]
- Nigam, P.; Bhatt, S.P.; Misra, A.; Vaidya, M.; Dasgupta, J.; Chadha, D.S. Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India. PLoS ONE 2013, 8, e49286. [Google Scholar] [CrossRef] [Green Version]
- Yeniova, A.O.; Küçükazman, M.; Ata, N.; Dal, K.; Kefeli, A.; Başyiğit, S.; Aktaş, B.; Ağladioğlu, K.; Akin, K.O.; Ertugrul, D.T.; et al. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease. Hepatogastroenterology 2014, 61, 422–425. [Google Scholar]
- Gao, B.; Tsukamoto, H. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? Gastroenterology 2016, 150, 1704–1709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blumberg, J.B.; Frei, B.; Fulgoni, V.L., III; Weaver, C.M.; Zeisel, S.H. Contribution of Dietary Supplements to Nutritional Adequacy in Race/Ethnic Population Subgroups in the United States. Nutrients 2017, 9, 1295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sigrist, R.M.; Liau, J.; El Kaffas, A.; Chammas, M.C.; Willmann, J.K. Ultrasound Elastography: Review of Techniques and Clinical Applications. Theranostics 2017, 7, 1303–1329. [Google Scholar] [CrossRef] [PubMed]
- Murakami, K.; Livingstone, M.B.E. Prevalence and characteristics of misreporting of energy intake in US adults: NHANES 2003–2012. Br. J. Nutr. 2015, 114, 1294–1303. [Google Scholar] [CrossRef] [Green Version]
Characteristics | Black | Hispanic | White | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All | Non-Steatosis | Steatosis | pa | All | Non-Steatosis | Steatosis | pa | All | Non-Steatosis | Steatosis | pa | |
N | 1037 | 804 | 233 | 981 | 626 | 355 | 1549 | 1055 | 494 | |||
Age (y) | 45.8 ± 0.6 | 44.6 ± 0.7 | 50.4 ± 1.1 | 0.0001 | 43.0 ± 0.9 | 41.7 ± 1.0 | 45.7 ± 1.1 | 0.0002 | 50.3± 0.9 | 49.0± 1.0 | 53.6± 0.9 | 0.0001 |
Sex, (%) | 0.39 | 0.001 | <0.0001 | |||||||||
Men | 47.4 | 46.2 | 51.7 | 51.0 | 46.6 | 59.4 | 49.6 | 44.6 | 62.0 | |||
Women | 52.6 | 53.8 | 48.3 | 50.0 | 53.4 | 40.6 | 50.4 | 55.4 | 38.0 | |||
Education (%) | 0.04 | 0.01 | 0.0003 | |||||||||
Below high school | 11.5 | 11.1 | 12.9 | 26.8 | 28.1 | 24.3 | 6.1 | 6.0 | 6.6 | |||
High school/some college | 67.4 | 66.1 | 72.2 | 57.3 | 54.3 | 63.2 | 59.0 | 56.5 | 65.3 | |||
College graduate | 21.1 | 22.8 | 14.9 | 15.9 | 17.7 | 12.5 | 34.9 | 37.5 | 28.1 | |||
Body mass index (kg/m2) | 31.1 ± 0.3 | 29.3 ± 0.2 | 38.1 ± 0.6 | <0.0001 | 30.4 ± 0.3 | 28.4 ± 0.4 | 34.3 ± 0.6 | <0.0001 | 29.6 ± 0.4 | 29.0 ± 0.3 | 35.2 ± 0.6 | <0.0001 |
Obese (≥30 kg/m2) (%) | 49.1 | 38.6 | 88.7 | <0.0001 | 45.7 | 32.1 | 72.0 | <0.0001 | 42.5 | 29.0 | 75.9 | <0.0001 |
Smoke status (%) | 0.08 | 0.03 | <0.0001 | |||||||||
Never | 62.8 | 64.6 | 55.8 | 64.9 | 67.5 | 59.9 | 53.9 | 56.6 | 47.2 | |||
Former | 16.0 | 14.5 | 21.7 | 22.4 | 19.4 | 28.2 | 28.6 | 25.6 | 36.2 | |||
Current | 21.2 | 20.9 | 22.5 | 12.7 | 13.1 | 11.9 | 17.5 | 17.8 | 16.6 | |||
Alcohol drinking habits in past 12 months (%) | 0.42 | 0.33 | 0.07 | |||||||||
Never/rarely | 34.8 | 33.7 | 38.4 | 33.8 | 34.3 | 32.8 | 30.6 | 28.1 | 37.0 | |||
Occasionally | 24.4 | 24.2 | 25.4 | 22.6 | 23.1 | 21.4 | 21.7 | 21.2 | 22.8 | |||
Sometimes | 27.0 | 27.8 | 24.1 | 34.9 | 35.3 | 34.1 | 31.8 | 33.7 | 27.0 | |||
Frequently | 13.8 | 14.3 | 12.1 | 8.7 | 7.3 | 11.5 | 15.9 | 17.0 | 13.2 | |||
Diabetes (%) | 14.8 | 11.1 | 28.8 | <0.0001 | 12.0 | 7.5 | 20.8 | <0.0001 | 13.4 | 7.2 | 29.0 | <0.0001 |
High blood pressure (%) | 40.4 | 35.2 | 59.4 | <0.0001 | 22.1 | 17.3 | 31.5 | <0.0001 | 33.1 | 25.7 | 51.8 | <0.0001 |
HBV infection (%) b | 6.5 | 6.1 | 8.0 | 0.69 | 2.8 | 2.1 | 4.2 | 0.18 | 2.7 | 2.1 | 3.9 | 0.11 |
HCV infection (%) c | 2.8 | 2.7 | 3.2 | 0.34 | 1.7 | 1.3 | 2.4 | 0.12 | 3.2 | 3.5 | 2.3 | 0.50 |
AST (IU/L) d | 21.5 ± 0.4 | 21.1 ± 0.6 | 23.0 ± 0.9 | 0.08 | 22.6 ± 0.6 | 20.9 ± 0.4 | 26.0 ± 1.2 | <0.0001 | 22.4 ± 0.5 | 21.7 ± 0.6 | 24.2 ± 1.0 | <0.0001 |
ALT (IU/L) e | 20.1 ± 0.6 | 18.6 ± 0.7 | 25.6 ± 0.9 | <0.0001 | 25.9 ± 0.7 | 22.3 ± 0.7 | 32.8 ± 1.4 | <0.0001 | 23.2 ± 0.7 | 20.7 ± 0.6 | 29.5 ± 1.6 | <0.0001 |
HS-CRP (mg/L) f | 4.6 ± 0.1 | 3.8 ± 0.2 | 7.7 ± 0.5 | <0.0001 | 3.8 ± 0.3 | 3.4 ± 0.3 | 4.6 ± 0.3 | 0.002 | 3.7 ± 0.2 | 3.0 ± 0.3 | 5.5 ± 0.4 | <0.0001 |
Dietary intake | ||||||||||||
Total energy (kcal) | 2126 ± 33 | 2127 ± 40 | 2121 ± 86 | 0.84 | 2233 ± 31 | 2186 ± 39 | 2324± 65 | 0.40 | 2209 ± 27 | 2172 ± 38 | 2302 ± 47 | 0.53 |
α-Tocopherol (mg/day) | 8.9 ± 0.3 | 8.9 ± 0.3 | 8.1 ± 0.4 | 0.03 | 9.3 ± 0.3 | 9.4 ± 0.4 | 9.1 ± 0.3 | 0.34 | 9.6 ± 0.3 | 9.8 ± 0.3 | 8.9 ± 0.3 | 0.16 |
Retinol (µg/day) | 343 ± 17 | 345 ± 21 | 336 ± 26 | 0.42 | 379 ± 19 | 375 ± 24 | 387 ± 26 | 0.71 | 444 ± 9 | 448 ± 11 | 436 ± 25 | 0.64 |
Vitamin D (µg/day) g | 22.1 ± 7.0 | 22.0 ± 8.6 | 22.6 ± 7.3 | 0.45 | 12.6 ± 0.7 | 13.1 ± 0.7 | 11.5 ± 1.4 | 0.61 | 27.2 ± 3.4 | 27.0 ± 4.7 | 27.7 ± 3.4 | 0.94 |
β-Carotene (µg/day) | 2328 ± 242 | 2463 ± 282 | 1821 ± 230 | 0.48 | 2508 ± 235 | 2659 ± 269 | 2215 ± 308 | 0.24 | 2429 ± 200 | 2452 ± 217 | 2371 ± 340 | 0.53 |
Tot carotenoid (µg/day) h | 8868 ± 413 | 9261 ± 445 | 7385 ± 732 | 0.005 | 10743 ± 745 | 11036 ± 942 | 10175 ± 888 | 0.68 | 9181 ± 403 | 9344 ± 509 | 8774 ± 724 | 0.42 |
Take supplement (%) | 47.4 | 46.0 | 52.5 | 0.28 | 49.7 | 51.7 | 45.9 | 0.02 | 61.1 | 61.7 | 59.6 | 0.47 |
Micronutrients | OR (95% CI) a | Ptrenda | |||
---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | ||
α-Tocopherol (mg/day) | |||||
Quartile range | <4.4 | 4.4–6.9 | 6.9–10.5 | ≥10.5 | |
Number of participants | 964 | 1031 | 1113 | 1268 | |
Number of cases | 293 | 299 | 344 | 361 | |
Model 1 b | 1.00 | 0.76 (0.58–0.99) | 0.81 (0.54–1.21) | 0.54 (0.39–0.76) | 0.002 |
Model 2 c | 1.00 | 0.81 (0.60–1.10) | 0.83 (0.55–1.26) | 0.51 (0.35–0.74) | 0.0003 |
Retinol (µg/day) | |||||
Quartile range | <161.0 | 161.0–333.0 | 333.0–561.0 | ≥561.0 | |
Number of participants | 1268 | 1118 | 1027 | 963 | |
Number of cases | 360 | 335 | 307 | 295 | |
Model 1 b | 1.00 | 1.04 (0.75–1.44) | 0.74 (0.50–1.11) | 0.88 (0.54–1.46) | 0.53 |
Model 2 c | 1.00 | 1.00 (0.71–1.42) | 0.73 (0.48–1.09) | 0.86 (0.52–1.44) | 0.51 |
Vitamin D (µg/day) d | |||||
Quartile range | <1.7 | 1.7–4.8 | 4.8–13.3 | ≥13.3 | |
Number of participants | 1179 | 1053 | 809 | 1335 | |
Number of cases | 320 | 304 | 258 | 415 | |
Model 1 b | 1.00 | 0.96 (0.71–1.31) | 1.00 (0.70–1.45) | 1.09 (0.78–1.54) | 0.41 |
Model 2 c | 1.00 | 0.93 (0.67–1.30) | 0.98 (0.67–1.45) | 0.99 (0.69–1.43) | 0.87 |
β-Carotene (µg/day) | |||||
Quartile range | <217.0 | 217.0–615.0 | 615.0–1924.5 | ≥1924.5 | |
Number of participants | 857 | 995 | 1202 | 1322 | |
Number of cases | 243 | 326 | 378 | 350 | |
Model 1 b | 1.00 | 1.08 (0.81–1.45) | 1.14 (0.86–1.53) | 0.85 (0.63–1.15) | 0.03 |
Model 2 c | 1.00 | 1.16 (0.87–1.56) | 1.20 (0.86–1.66) | 0.87 (0.65–1.16) | 0.01 |
Total Carotenoids (µg/day) | |||||
Quartile range | <1429.5 | 1429.5–4380.5 | 4380.5–10563.0 | ≥10563.0 | |
Number of participants | 935 | 1039 | 1138 | 1264 | |
Number of cases | 289 | 296 | 344 | 368 | |
Model 1 b | 1.00 | 0.92 (0.64–1.32) | 0.87 (0.56–1.36) | 0.96 (0.66–1.39) | 0.93 |
Model 2 c | 1.00 | 1.00 (0.69–1.45) | 0.86 (0.52–1.43) | 0.99 (0.69–1.43) | 0.91 |
Micronutrients | Black | Hispanic | White | ||||||
---|---|---|---|---|---|---|---|---|---|
T1 | T2 | T3 | T1 | T2 | T3 | T1 | T2 | T3 | |
α-Tocopherol (mg/day) | |||||||||
Tertile range | <5.3 | 5.3–9.5 | ≥9.5 | <5.6 | 5.6–10.3 | ≥10.3 | <6.1 | 6.1–10.2 | ≥10.2 |
Participants (N) | 347 | 331 | 359 | 343 | 338 | 300 | 574 | 481 | 494 |
Cases (N) | 83 | 78 | 72 | 123 | 124 | 108 | 182 | 157 | 155 |
OR (95% CI) a | 1.00 | 0.96 (0.56–1.64) | 0.45 (0.26–0.77) | 1.00 | 1.57 (1.04–2.38) | 1.23 (0.81–1.88) | 1.00 | 0.99 (0.67–1.47) | 0.56 (0.33–0.94) |
Ptrenda = 0.002 | Ptrenda = 0.59 | Ptrenda = 0.02 | |||||||
Retinol (µg/day) | |||||||||
Tertile range | <135.2 | 135.2–364.2 | ≥364.2 | <182.5 | 182.5–427.8 | ≥427.8 | <246.2 | 246.2–491.2 | ≥491.2 |
Participants (N) | 341 | 338 | 358 | 319 | 344 | 318 | 505 | 482 | 562 |
Cases (N) | 67 | 91 | 75 | 117 | 119 | 119 | 158 | 156 | 180 |
OR (95% CI) a | 1.00 | 1.20 (0.83–1.73) | 0.94 (0.48–1.84) | 1.00 | 0.88 (0.60–1.34) | 1.20 (0.66–2.22) | 1.00 | 0.73 (0.42–1.27) | 0.77 (0.40–1.50) |
Ptrenda = 0.75 | Ptrenda = 0.47 | Ptrenda = 0.52 | |||||||
Vitamin D (µg/day) b | |||||||||
Tertile range | <1.5 | 1.5–6.7 | ≥6.7 | <1.9 | 1.9–6.2 | ≥6.2 | <2.9 | 2.9–15.9 | ≥15.9 |
Participants (N) | 319 | 344 | 374 | 301 | 317 | 363 | 489 | 517 | 543 |
Cases (N) | 57 | 83 | 93 | 107 | 122 | 126 | 154 | 170 | 170 |
OR (95% CI) a | 1.00 | 1.03 (0.72–1.47) | 0.99 (0.53–1.83) | 1.00 | 1.03 (0.57–1.86) | 0.86 (0.55–1.36) | 1.00 | 0.96 (0.64–1.42) | 0.91 (0.57–1.45) |
Ptrenda = 0.93 | Ptrenda = 0.37 | Ptrenda = 0.68 | |||||||
β-Carotene (µg/day) | |||||||||
Tertile range | <333.1 | 333.1–1254.2 | ≥1254.2 | <554.8 | 554.8–1836.6 | ≥1836.6 | <411.1 | 411.1–1600.6 | ≥1600.6 |
Participants (N) | 348 | 328 | 361 | 313 | 332 | 336 | 567 | 499 | 483 |
Cases (N) | 69 | 89 | 75 | 116 | 124 | 115 | 184 | 170 | 140 |
OR (95% CI) a | 1.00 | 1.39 (0.94–2.07) | 1.07 (0.59–1.95) | 1.00 | 0.88 (0.54–1.45) | 0.74 (0.51–1.07) | 1.00 | 1.60 (1.08–2.39) | 0.99 (0.75–1.31) |
Ptrenda = 0.77 | Ptrenda = 0.11 | Ptrenda = 0.22 | |||||||
Total carotenoids (µg/day) | |||||||||
Tertile range | <2009.8 | 2009.8–7732.4 | ≥7732.4 | <3464.6 | 3464.6–10075.0 | ≥10075.0 | 3005.4 | 3005.4–9489.2 | ≥9489.2 |
Participants (N) | 352 | 338 | 347 | 340 | 329 | 312 | 562 | 508 | 479 |
Cases (N) | 72 | 90 | 71 | 129 | 114 | 112 | 183 | 157 | 154 |
OR (95% CI) a | 1.00 | 1.49 (1.06–2.09) | 1.08 (0.60–1.93) | 1.00 | 0.84 (0.57–1.23) | 0.90 (0.48–1.69) | 1.00 | 0.96 (0.52–1.77) | 1.17 (0.67–2.03) |
Ptrenda = 0.77 | Ptrenda = 0.83 | Ptrenda = 0.53 |
Race/Ethnicity | Never/Rare/Occasional Alcohol Drinker | Sometimes/Frequent Alcohol Drinker | |||||||
---|---|---|---|---|---|---|---|---|---|
Quartile (Q1–Q4)/Tertile (T1–T3) | Participants (N) | Cases (N) | OR (95%CI) a | Ptrenda | Participants (N) | Cases (N) | OR (95%CI) a | Ptrenda | |
All participants | α-Tocopherol (mg/day) | ||||||||
Q1 (<4.4) | 646 | 201 | 1.00 | 294 | 83 | 1.00 | |||
Q2 (4.4–6.9) | 646 | 197 | 0.83 (0.55–1.26) | 361 | 99 | 0.98 (0.67–1.42) | |||
Q3 (6.9–10.5) | 655 | 209 | 0.78 (0.46–1.33) | 430 | 131 | 1.02 (0.54–1.94) | |||
Q4 (≥10.5) | 721 | 220 | 0.49 (0.27–0.89) | 0.016 | 509 | 131 | 0.60 (0.32–1.13) | 0.06 | |
Retinol (µg/day) | |||||||||
Q1 (<161.0) | 777 | 229 | 1.00 | 449 | 117 | 1.00 | |||
Q2 (161.0–333.0) | 681 | 214 | 1.08 (0.72–1.60) | 412 | 117 | 1.13 (0.70–1.83) | |||
Q3 (333.0–561.0) | 613 | 191 | 0.92 (0.48–1.74) | 385 | 112 | 0.63 (0.41–0.97) | |||
Q4 (≥561.0) | 597 | 193 | 1.02 (0.59–1.77) | 0.95 | 348 | 98 | 0.76 (0.34–1.69) | 0.38 | |
Vitamin D (µg/day) b | |||||||||
Q1 (<1.7) | 707 | 208 | 1.00 | 440 | 105 | 1.00 | |||
Q2 (1.7–4.8) | 619 | 189 | 1.22 (0.79–1.90) | 407 | 108 | 0.70 (0.37–1.31) | |||
Q3 (4.8–13.3) | 478 | 150 | 0.89 (0.54–1.44) | 305 | 102 | 1.11 (0.65–1.91) | |||
Q4 (≥13.3) | 864 | 280 | 0.92 (0.57–1.50) | 0.47 | 442 | 129 | 1.15 (0.63–2.11) | 0.28 | |
β-Carotene (µg/day) | |||||||||
Q1 (<217.0) | 560 | 165 | 1.00 | 275 | 72 | 1.00 | |||
Q2 (217.0–615.0) | 597 | 204 | 1.08 (0.72–1.61) | 375 | 116 | 1.54 (0.87–2.71) | |||
Q3 (615.0–1924.5) | 722 | 236 | 1.36 (0.89–2.08) | 447 | 136 | 1.19 (0.76–1.86) | |||
Q4 (≥1924.5) | 789 | 222 | 0.78 (0.54–1.14) | 0.007 | 497 | 120 | 1.13 (0.62–2.08) | 0.47 | |
Total carotenoids (µg/day) | |||||||||
Q1 (<1429.5) | 609 | 200 | 1.00 | 303 | 81 | 1.00 | |||
Q2 (1429.5–4380.5) | 630 | 179 | 0.92 (0.55–1.54) | 381 | 115 | 1.49 (1.06–2.10) | |||
Q3 (4380.5–10563.0) | 689 | 218 | 0.93 (0.50–1.74) | 415 | 114 | 0.95 (0.42–2.18) | |||
Q4 (≥10563.0) | 740 | 230 | 0.91 (0.67–1.23) | 0.66 | 495 | 134 | 1.36 (0.67–2.79) | 0.62 | |
Black participants | α-Tocopherol (mg/day) | ||||||||
T1 (<5.3) | 211 | 54 | 1.00 | 126 | 29 | 1.00 | |||
T2 (5.3–9.5) | 193 | 46 | 0.94 (0.52–1.71) | 129 | 31 | 0.92 (0.37–2.30) | |||
T3 (≥9.5) | 206 | 45 | 0.37 (0.18–0.73) | 0.003 | 141 | 24 | 0.61 (0.24–1.56) | 0.29 | |
Retinol (µg/day) | |||||||||
T1 (<135.2) | 198 | 44 | 1.00 | 132 | 22 | 1.00 | |||
T2 (135.2–364.2) | 185 | 47 | 1.15 (0.78–1.69) | 145 | 43 | 1.10 (0.55–2.19) | |||
T3 (≥364.2) | 227 | 54 | 1.17 (0.68–2.01) | 0.65 | 119 | 19 | 0.41 (0.11–1.44) | 0.13 | |
Vitamin D (µg/day) b | |||||||||
T1 (<1.5) | 182 | 38 | 1.00 | 129 | 19 | 1.00 | |||
T2 (1.5–6.7) | 195 | 47 | 0.74 (0.48–1.14) | 137 | 32 | 1.25 (0.79–1.98) | |||
T3 (≥6.7) | 233 | 60 | 0.94 (0.49–1.83) | 0.75 | 130 | 33 | 0.88 (0.30–2.59) | 0.68 | |
β-Carotene (µg/day) | |||||||||
T1 (<333.1) | 208 | 46 | 1.00 | 129 | 23 | 1.00 | |||
T2 (333.1–1254.2) | 183 | 51 | 1.02 (0.60–1.74) | 138 | 37 | 2.07 (0.79–5.40) | |||
T3 (≥554.8) | 219 | 48 | 0.87 (0.41–1.87) | 0.65 | 129 | 24 | 1.46 (0.72–2.99) | 0.94 | |
Total carotenoids (µg/day) | |||||||||
T1 (<2009.8) | 211 | 48 | 1.00 | 133 | 24 | 1.00 | |||
T2 (2009.8–7732.4) | 189 | 52 | 1.47 (0.74–2.95) | 141 | 38 | 1.74 (0.91–3.33) | |||
T3 (≥7732.4) | 210 | 45 | 0.80 (0.39–1.64) | 0.22 | 122 | 22 | 2.07 (0.92–4.66) | 0.13 | |
Hispanic participants | α-Tocopherol (mg/day) | ||||||||
T1 (<5.6) | 226 | 76 | 1.00 | 106 | 40 | 1.00 | |||
T2 (5.6–10.3) | 200 | 65 | 1.18 (0.66–2.14) | 130 | 57 | 2.62 (1.17–5.86) | |||
T3 (≥10.3) | 171 | 64 | 1.20 (0.77–1.87) | 0.45 | 117 | 40 | 1.57 (0.85–2.89) | 0.53 | |
Retinol (µg/day) | |||||||||
T1 (<182.5) | 194 | 68 | 1.00 | 114 | 43 | 1.00 | |||
T2 (182.5–427.8) | 208 | 65 | 0.70 (0.40–1.22) | 124 | 48 | 1.11 (0.49–2.52) | |||
T3 (≥427.8) | 195 | 72 | 0.95 (0.42–2.14) | 0.76 | 115 | 46 | 1.63 (0.84–3.16) | 0.11 | |
Vitamin D (µg/day) b | |||||||||
T1 (<1.9) | 191 | 67 | 1.00 | 102 | 36 | 1.00 | |||
T2 (1.9–6.2) | 190 | 65 | 0.67 (0.35–1.25) | 114 | 53 | 1.84 (0.70–4.81) | |||
T3 (≥6.2) | 216 | 73 | 0.91 (0.56–1.48) | 0.73 | 137 | 48 | 0.72 (0.35–1.44) | 0.08 | |
β-Carotene (µg/day) | |||||||||
T1 (<554.8) | 202 | 73 | 1.00 | 118 | 51 | 1.00 | |||
T2 (554.8–1836.6) | 207 | 73 | 0.89 (0.44–1.81) | 119 | 46 | 0.83 (0.48–1.44) | |||
T3 (≥1836.6) | 188 | 59 | 0.93 (0.52–1.66) | 0.86 | 116 | 50 | 0.58 (0.30–1.13) | 0.15 | |
Total carotenoids (µg/day) | |||||||||
T1 (<3464.6) | 211 | 77 | 1.00 | 117 | 46 | 1.00 | |||
T2 (3464.6–10075.0)) | 196 | 62 | 0.83 (0.47–1.46) | 119 | 46 | 0.89 (0.40–1.97) | |||
T3 (≥10075.0) | 190 | 66 | 1.04 (0.57–1.90) | 0.77 | 117 | 45 | 0.76 (0.25–2.34) | 0.65 | |
White participants | α-Tocopherol (mg/day) | ||||||||
T1 (<6.1) | 370 | 126 | 1.00 | 197 | 54 | 1.00 | |||
T2 (6.1–10.2) | 274 | 102 | 1.17 (0.73–1.89) | 202 | 54 | 0.80 (0.39–1.65) | |||
T3 (≥10.2) | 274 | 91 | 0.56 (0.25–1.27) | 0.11 | 211 | 62 | 0.51 (0.24–1.10) | 0.09 | |
Retinol (µg/day) | |||||||||
T1 (<246.2) | 308 | 106 | 1.00 | 190 | 50 | 1.00 | |||
T2 (246.2–491.2) | 266 | 101 | 0.83 (0.41–1.71) | 207 | 54 | 0.64 (0.39–1.05) | |||
T3 (≥491.2) | 344 | 112 | 0.82 (0.37–1.81) | 0.63 | 213 | 66 | 0.60 (0.25–1.46) | 0.33 | |
Vitamin D (µg/day) b | |||||||||
T1 (<2.9) | 282 | 96 | 1.00 | 201 | 56 | 1.00 | |||
T2 (2.9–15.9) | 284 | 109 | 1.24 (0.76–2.04) | 227 | 60 | 0.70 (0.41–1.19) | |||
T3 (≥15.9) | 352 | 114 | 0.77 (0.40–1.48) | 0.24 | 182 | 54 | 1.34 (0.63–2.85) | 0.18 | |
β-Carotene (µg/day) | |||||||||
T1 (<411.1) | 375 | 129 | 1.00 | 188 | 53 | 1.00 | |||
T2 (411.1–1600.6) | 296 | 111 | 1.81 (1.04–3.17) | 194 | 58 | 1.23 (0.67–2.24) | |||
T3 (≥1600.6) | 247 | 79 | 0.81 (0.56–1.16) | 0.01 | 228 | 59 | 1.14 (0.63–2.05) | 0.90 | |
Total carotenoids (µg/day) | |||||||||
T1 (<3005.4) | 375 | 128 | 1.00 | 181 | 53 | 1.00 | |||
T2 (3005.4–9489.2) | 294 | 103 | 0.91 (0.45–1.86) | 204 | 52 | 1.15 (0.45–2.90) | |||
T3 (≥9489.2) | 249 | 88 | 0.96 (0.58–1.58) | 0.77 | 225 | 65 | 1.50 (0.53–4.04) | 0.65 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chai, W.; Eaton, S.; Rasmussen, H.E.; Tao, M.-H. Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States. Biomedicines 2021, 9, 1093. https://doi.org/10.3390/biomedicines9091093
Chai W, Eaton S, Rasmussen HE, Tao M-H. Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States. Biomedicines. 2021; 9(9):1093. https://doi.org/10.3390/biomedicines9091093
Chicago/Turabian StyleChai, Weiwen, Sarah Eaton, Heather E. Rasmussen, and Meng-Hua Tao. 2021. "Associations of Dietary Lipid-Soluble Micronutrients with Hepatic Steatosis among Adults in the United States" Biomedicines 9, no. 9: 1093. https://doi.org/10.3390/biomedicines9091093